The tweet was deleted by the author.
But we saved everything 🙂.
Tenaya Therapeutics unveiled interim results from its RIDGE-1 Phase 1b/2 trial at #ASGCT, indicating consistent reductions in arrhythmias among adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
The data relate to the investigational gene therapy candidate TN-401, which aims to address inherited arrhythmia syndromes. Further details about the trial and findings are available on the company’s official website.
View post on X Loading...
Tenaya Therapeutics previously announced plans to present new clinical data from the RIDGE-1 TN-401 trial during a late breaking session at ASGCT, according to a company statement earlier this year. Separately, Tenaya also recognized Eugene Braunwald for his contributions to hypertrophic cardiomyopathy and modern cardiology at a recent event. The company continues to advance research in inherited cardiac conditions.